Heterogeneity of excision repair cross‑complementation group 1 gene expression in non‑small‑cell lung cancer patients

Smirnov,Serhey; Pashkevich,Anastasiya; Liundysheva,Valeriya; Babenko,Andrey; Smolyakova,Raisa

doi:10.3892/mco.2014.415

Heterogeneity of excision repair cross‑complementation group 1 gene expression in non‑small‑cell lung cancer patients

Authors:
- Serhey Smirnov
- Anastasiya Pashkevich
- Valeriya Liundysheva
- Andrey Babenko
- Raisa Smolyakova
View Affiliations

Affiliations: Department of Carcinogenesis, Alexandrov N.N. National Cancer Center for Oncology and Medical Radiology, Minsk 223040, Belarus
Published online on: September 10, 2014 https://doi.org/10.3892/mco.2014.415
Pages: 227-231

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Excision repair cross‑complementation group 1 (ERCC1) gene expression analysis is currently used widely in the molecular diagnosis of cancer. According to numerous studies, ERCC1 gene expression correlates with overall survival and effectiveness of chemotherapy with platinum agents. However, the degree of this correlation differs among various studies, with certain authors reporting a complete lack of such a correlation. These contradictions may be attributed to a number of factors, including the heterogeneity of the tumor tissue. In this study, we attempted to assess the degree of genetic heterogeneity exhibited by tissue samples obtained from non‑small‑cell lung cancer (NSCLC) through the expression of the ERCC1 gene. This study included 25 samples of tumor tissue from patients with a morphologically confirmed NSCLC diagnosis. a total of three randomized sections of each specimen were used. The ERCC1 gene expression was assessed by quantitative polymerase chain reaction (qPCR) in the TaqMan format. When planning the experiment and analysis of qPCR data, the MIQE guidelines were taken into consideration. We established that the coefficient of variation of the relative level of ERCC1 gene expression in the majority of the samples exceeded 33% (p<0.05), indicating the significant heterogeneity of the sample. We also demonstrated that the degree of heterogeneity of the tumor tissue is largely dependent on disease stage.

View Figures

View References

1	Spyratos D, Zarogoulidis P, Porpodis K, et al: Preoperative evaluation for lung cancer resection. J Thorac Dis. 6 Suppl 1:S162–S166. 2014.
2	Sculier JP, Meert AP and Berghmans T: Updates in oncology. Eur Respir Rev. 23:69–78. 2014. View Article : Google Scholar : PubMed/NCBI
3	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
4	Barlesi F, Pujol JL and Daures JP: Should chemotherapy (Cx) for advanced non-small cell lung cancer (NSCLC) be platinum-based? A literature-based meta-analysis of randomized trials. J Clin Oncol. 23:72132005.
5	D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T and Shepherd FA: Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 23:2926–2936. 2005.PubMed/NCBI
6	Yan D, Wei P, An G and Chen W: Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer. J Cardiothorac Surg. 8:1492013. View Article : Google Scholar : PubMed/NCBI
7	Leibeling D, Laspe P and Emmert S: Nucleotide excision repair and cancer. J Mol Histol. 37:225–238. 2006. View Article : Google Scholar : PubMed/NCBI
8	Fuertes MA, Castilla J, Alonso C and Perez JM: Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem. 10:257–266. 2003. View Article : Google Scholar
9	Sakano S, Ogawa S, Yamamoto Y, Nishijima J, Miyachika Y, Matsumoto H, Hara T and Matsuyama H: ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy. Mol Clin Oncol. 1:403–410. 2013.PubMed/NCBI
10	Rosell R, Taron M, Camps C and Lopez-Vivanco G: Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today (Barc). 39:775–786. 2003. View Article : Google Scholar : PubMed/NCBI
11	Bergot E, Levallet G, Campbell K, Dubois F, Lechapt E and Zalcman G: Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy. Eur Respir Rev. 22:565–576. 2013. View Article : Google Scholar : PubMed/NCBI
12	Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS and Christiani DC: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 22:2594–2601. 2004. View Article : Google Scholar : PubMed/NCBI
13	Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, Ryu JK, Bosch W and Emami B: Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 61:318–328. 2005. View Article : Google Scholar : PubMed/NCBI
14	Lord RV, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 8:2286–2291. 2002.PubMed/NCBI
15	Lee MR, Cho SH, Kim DC, Lee KC, Lee JH, Kwon HC, Lee HW and Lee SE: Concordance between immunohistochemistry and FISH (fluorescence in situ hybridization) & SISH (silver in situ hybridization) for assessment of the HER2. Cancer Res. 72 Suppl 3:PD02–PD06. 2012.
16	Besse B, Olaussen KA and Soria JC: ERCC1 and RRM1: ready for prime time? J Clin Oncol. 31:1050–1060. 2013. View Article : Google Scholar : PubMed/NCBI
17	Friboulet L, Olaussen KA, Pignon JP, et al: ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 368:1101–1110. 2013. View Article : Google Scholar : PubMed/NCBI
18	Chang MC: Letter to the editor regarding ‘Seol H, Lee HJ, Choi Y, et al: Intratumoural heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance’. Mod Pathol. 26:609–610. 2013.
19	Bachtiary B, Boutros PC, Pintilie M, et al: Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. Clin Cancer Res. 12:5632–5640. 2006. View Article : Google Scholar : PubMed/NCBI
20	Michor F and Polyak K: The origins and implications of intratumor heterogeneity. Cancer Prev Res (Phila). 3:1361–1364. 2010. View Article : Google Scholar : PubMed/NCBI
21	Burrell RA, McGranahan N, Bartek J and Swanton C: The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 501:338–345. 2013. View Article : Google Scholar : PubMed/NCBI
22	Merlo LM and Maley CC: The role of genetic diversity in cancer. J Clin Invest. 120:401–403. 2010. View Article : Google Scholar : PubMed/NCBI
23	Ng CK, Pemberton HN and Reis-Filho JS: Breast cancer intratumor genetic heterogeneity: causes and implications. Expert Rev Anticancer Ther. 12:1021–1032. 2012. View Article : Google Scholar : PubMed/NCBI
24	Anaka M, Hudson C, Lo PH, Do H, Caballero OL, Davis ID, Dobrovic A, Cebon J and Behren A: Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors. BMC Med Genomics. 6:402013. View Article : Google Scholar : PubMed/NCBI
25	Losi L, Baisse B, Bouzourene H and Benhattar J: Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis. 26:916–922. 2005. View Article : Google Scholar : PubMed/NCBI
26	Saeki R, Nagai H, Kaneko S, Unoura M, Yamanaka N, Okamoto E, Kobayashi K and Matsubara K: Intratumoral genomic heterogeneity in human hepatocellular carcinoma detected by restriction landmark genomic scanning. J Hepatol. 33:99–105. 2000. View Article : Google Scholar
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Sipos F, Constantinovits M and Műzes G: Intratumoral functional heterogeneity and chemotherapy. World J Gastroenterol. 20:2429–2432. 2014. View Article : Google Scholar : PubMed/NCBI
29	Bedard PL, Hansen AR, Ratain MJ and Siu LL: Tumour heterogeneity in the clinic. Nature. 501:355–364. 2013. View Article : Google Scholar : PubMed/NCBI
30	Bustin SA, Benes V, Garson JA, et al: The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 55:611–622. 2009. View Article : Google Scholar : PubMed/NCBI
31	Greaves M and Maley CC: Clonal evolution in cancer. Nature. 481:306–313. 2012. View Article : Google Scholar : PubMed/NCBI
32	Jian-Wei B, Yi-Min M, Yu-Xia S and Shi-Qing L: Expression levels of ERCC1 and RRM1 mRNA and clinical outcome of advanced non-small cell lung cancer. Pak J Med Sci. 29:1158–1161. 2013.PubMed/NCBI
33	Yamashita F, Azuma K, Yoshida T, Yamada K, Kawahara A, Hattori S, Takeoka H, Zaizen Y, Kawayama T, Kage M and Hoshino T: Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy. PLoS One. 8:e713562013. View Article : Google Scholar : PubMed/NCBI